How to understand your disease
of aging : ageless man
Ageless Man
Androgenic Disease of Andropause
(Broad Overview)
Georges Debled
(October 5, 2019
-
SEMAL Congress Seville)
Introduction
In
recent years in the USA, prescription of
testosterone in gel, injections or tablets in
men having biology known as
Low
Testosterone has undergone considerable
growth. “Testosterone clinics” have
proliferated. By lack of discernment,
“testosterone treatment” has given rise to
severe cardiovascular complications and a
multitude of class actions. Just check Google
with keywords "testosterone " and "class
actions" to see the number of lawsuits underway
in 2019 in the US. Complaints concern patients,
pharmaceutical companies, and insurances.
Everyone rejects the responsibility for the
disasters caused by the use of testosterone. In
reality, all actors in these legal proceedings
can both right and wrong. The problem comes
from the
fact that
Low Testosterone Syndrome is not so easy to
assess and that “andropause” is not a disease.
Class actions are the consequences of disasters
caused by testosterone treatments for signs that
are not diseases (andropause — Low testosterone)
while
Androgenic Disease of Andropause
and
its treatment by mesterolone are constantly
ignored or poorly understood.
History
“Andropause disease” was described more than
thirty years ago [1-2-3]. However, “andropause”
is still considered today as a non-pathological
natural phenomenon such as menopause that is not
a disease.
The expression
Male
Menopause
is
also commonly used, which makes no sense
since man has no menstruations.
The purpose of this communication is to define
the broad outlines of the
Androgenic
Disease
of Andropause—in short, “Andropause disease,”
it's diagnostic and its safe treatment by
mesterolone on thousands of patients for forty
years.
Definition
To define Andropause disease or Androgenic
Disease of Andropause is not easy since
there is no previous reference. When I wrote
"Andropause, cause, consequences, and remedies
in 1987,", I described not only a new concept
but also a new disease. I chose the word
andropause by what the dictionary described—in
French, since 1952, the main symptom of the
disease: "The natural cessation of sexual
function in elderly men." (Le Petit Robert). In
fact, after fourteen years’ experience starting
in 1974, I described the “andropause disease”
that has a cause: a decrease in secretion of
androgens (testosterone and dihydrotestosterone)
with age; has consequences: sexual impairment
with or without general disorders; has a
specific treatment with mesterolone that has
properties of dihydrotestosterone) (mesterolone
exists only since 1967).
"Andropause Disease" — the Androgenic
Disease of Andropause is the whole of
physiological and psychological changes
that accompany the natural and gradual cessation
of sexual activity in man as a result of the
decreased production of androgens (testosterone
and dihydrotestosterone)
[1]. Symptoms of androgen deficiency are well
known [4].
Diagnostic
Androgen hormone production is a chain of
biochemical reactions that starts with the
transformation of cholesterol through various
reactions to testosterone and ends with the
production of dihydrotestosterone.
If the production of testosterone decreases with
time (before or after forty), the decrease of
dihydrotestosterone occurs first, and its
metabolite
androstanediol glucuronide also
.
The man before and under Androgenic
Andropause Disease:
Plasmatic hormonal concentrations in
nanograms (ng) /100 ml
|
|
Normal
|
Androgenic Disease of Andropause
|
Testosterone
|
1000 - 800 ng/100ml
|
400 ng/100ml
|
Dihydrotestosterone (DHT)
|
100ng /100ml
|
+ or - 20 ng/ 100ml
|
*
The standards depend on the methods of analysis.
That's why we always must refer to the same
laboratory
It is thus possible to confirm also
discrepancies between the level of testosterone
and dihydrotestosterone if there is an early
defect of 5 alpha-reductase.
The defect of dihydrotestosterone causes
sclerosis of the prostatic musculature
aggravated by the excess of estradiol [5-6].
Treatment
If there are no clinical or biochemical symptoms
of sexual impairment, there is no andropause
disease. If there is no disease, no hormonal
treatment is justified.
Andropause disease occurs from forty and
sometimes even before. It appears when
androgens' production decreases significantly.
Mesterolone is
the ideal treatment.
The mesterolone molecule is a molecule of
dihydrotestosterone on which a methyl radical
has been grafted to C1. Through the liver,
mesterolone loses its methyl radical, and
dihydrotestosterone is released into the blood.
As dihydrotestosterone has certain properties of
testosterone, it can also compensate for
testosterone deficiency without inhibiting the
pituitary gland.
Under these conditions, the simplistic treatment
with testosterone is contraindicated and can be
harmful as evidenced by the many class actions
in the US. Testosterone can be converted into
estradiol, which aggravates genital symptoms and
causes water retention before heart failure.
While dihydrotestosterone gel inhibits the
pituitary gland,
mesterolone doesn’t and doses of 25 to 75
milligrams a day it is quite able to compensate
for deficiencies in dihydrotestosterone and even
testosterone without any danger whatsoever.
Mesterolone such as dihydrotestosterone cannot
be converted to estradiol. Intake of mesterolone
increases levels of 17 ketosteroids and
androstanediol
glucuronide in urine over 24 hours.
Continuous treatments for forty years on
thousands of cases have demonstrated the perfect
harmlessness of this treatment as well as
standardization of general biology in blood:
evolution of red and white blood cells number
glucose, cholesterol, triglycerides, fluidity
(antithrombin and others fluidity agents), total
proteins, total bilirubin.
Bibliography
1. DEBLED G. Course: The Androgenic Disease of
Andropause and Menopause. SEMAL. III Congreso
Intercontinental de Medicina Antienvejecimiento.
Hotel Hilton. Panamá 17 de marzo 2022, (In
Spanish).
2
.
DEBLED G. The Prevention of Prostate Adenoma.
SEMAL. III Congreso Intercontinental de Medicina
Antienvejecimiento. Hotel Hilton. Panamá 17-18
de marzo 2022, (In Spanish).
3.
DEBLED G. Composition for the treatment of
cancers.
OPRI (Office
belge de la propriété intellectuelle)
: 100075876.
Nº 2020/5139. March 02 2020.
4.
DEBLED
G. Adverse effects of 5-alpha-reductase
inhibitors. SEMAL: 2nd International
congress anti-aging medicine. Miami, February 6th
to 9th,2020
5.
DEBLED G.
Steroid hormone for the prevention of diseases
associated with aging.
(OPRI) Office belge de la propriété
intellectuelle:
100072468. Nº 2019/5905. December 13, 2019.
6.
DEBLED G. The androgenic disease of andropause.
SEMAL congress, Seville, October 5, 2019.
7.
DEBLED G. Ageless Man.
HMS WORLD. 2017
8.
DEBLED G.
The male climacteric, a prime cause of sex
involution. The tenth annual International
Symposium on man and his environment in health
and disease. February 27-March 1, 1992, Dallas.
Texas. the USA
9. DEBLED G.-
Andropause, Cause, Consequences, and Remedies
(in French). Maloine, Paris, 1988.
10. DEBLED G. L´hyperoestrogénie associée à la
dysectasie fibreuse (ou atrophie) de l'urètre
prostatique Bulletins et Mémoires de la Société
de Médecine de Paris: 7: 199-204, 1980
11. DEBLED G. L´hyperoestrogénie associée à la
dysectasie fibreuse (ou atrophie) de l'urètre
prostatique. Acta Urologica Belgica 47 : (3)
473-483, 1979)
http://www.georgesdebled.org/prostate%20atrophy.htm